Conventional chemoembolization using Lipiodol-based regimens was introduced in the 1980s, and it is currently recommended as the primary treatment modality for patients with unresectable, intermediate, or locally advanced hepatocellular carcinoma (HCC) by the international guidelines. For better therapeutic efficacy and safety, chemoembolization should be performed as selectively as possible through tumor-feeding arteries, based on the detection of arterial supply to the HCC. With the technical advancement of flat-panel detector, cone-beam computed tomography (CBCT) is mounted on the C-arm of the angiographic machine. CBCT facilitates the detection of small occult HCCs and fine tumor-feeding arteries, recognition of extrahepatic collateral supply, navigation of a microcatheter to the target feeding arteries, prevention of non-target embolization, and intraprocedural assessment of the completeness of treatment with chemoembolization. These functions performed by CBCT ultimately improve the safety and efficacy of chemoembolization and may contribute to improving the prognosis of the patient with HCC.
INTRODUCTION
Conventional transarterial chemoembolization (cTACE) using Lipiodol-based regimens was introduced in the 1980s, and its therapeutic efficacy in unresectable hepatocellular carcinoma (HCC) was reinforced by two randomized controlled trials. 1, 2 Currently, chemoembolization is recommended for patients with HCC as a palliative treatment modality by international guidelines [3] [4] [5] [6] and is more widely used than guideline recommendations in real-world practice. 7 Therefore, it is very important to improve the outcome of cTACE. For better therapeutic efficacy and safety of cTACE, it should be performed as selectively as possible through the tumor-feeding arteries. [8] [9] [10] With conventional angiographic systems, multiple angiography runs are usually needed to identify all the tumor-feeding arteries of the multiple and large tumors. In addition, it is not always easy to navigate a microcatheter to the target point through tortuous and branching arteries.
Recently, flat-panel detector systems have enabled us to perform real-time fluoroscopy, digital subtraction angiography (DSA), and cone-beam computed tomography (CBCT) in a single angiography unit. 11, 12 CBCT remarkably improved cTACE by providing high-resolution hepatic arteriographic catheterization, and it has become an essential tool for highly selective chemoembolization. 13 In this article, the role of CBCT guidance in superselective chemoembolization with
Lipiodol-based emulsion has been reviewed.
WHY A SUPERSELECTIVE PROCEDURE?
Because the majority of patients with HCC have underlying liver cirrhosis and impaired liver function, the overall survival is largely dependent on both tumor control and preservation of liver function. 4 To maximize local tumor control and to minimize liver damage, chemoembolization should be performed as selectively as possible through the tumor-feeding arteries.
The intra-arterial treatment options for HCCs are based on the assumption that HCCs are almost exclusively supplied by hepatic arteries. However, exclusive hepatic arterial supply is only true in well-encapsulated, nodular HCCs. In multistep hepatocarcinogenesis of HCC, portal venous supply remains in the early stage. 14 In advanced HCCs with a replacing or infiltrative growth pattern, the leading edge of the growing tumor receives dual blood supply from the hepatic artery and portal vein. In moderately differentiated HCCs, which have a pseudocapsule, peritumoral portal veins become tumor drainage vessels. Microsatellites may develop in the peritumoral area. 15 The persistent portal venous supply or microsatellites can be one of the major causes of incomplete treatment of HCCs by chemoembolization.
Lipiodol-based emulsion is advantageous for chemoembolization because of its physical properties. 16, 17 It can pass through a fine tumor-feeding artery, reach the tumor vessels, penetrate deeply into the tumor capsule, and accumulate in the peritumoral portal veins through either presinusoidal arterioportal communication or the tumor drainage route. 18 In a retrospective analysis of the clinical outcome of cTACE, local tumor recurrence was found to be significantly lower when more portal veins were visualized with Lipiodol during the procedure. When the peritumoral portal veins were extensively filled with Lipiodol, at least two-thirds of small HCCs were completely necrotized. 19, 20 However, it should be kept in mind that this ideal endpoint of "oily portogram" in cTACE can be achieved only in the case of selective catheterization of tumor-feeding arteries. Hence, a superselective procedure is essential to take advantage of Lipiodol-based emulsion in cTACE (Fig. 1) .
CBCT HEPATIC ARTERIOGRAPHY
The flat-panel detector has better contrast and spatial resolution than image intensifier systems and provides CBCT images by obtaining whole volume data set in a single C-arm rotation. Compared to multidetector CT (MDCT), CBCT has lower soft tissue contrast resolution because of lower detective quantum efficiency and lower tube voltage but higher spatial resolution because of a smaller focal spot and a larger matrix. 21 Furthermore, hepatic arteries can be better depicted with CBCT because of the direct injection of contrast media from target vessels instead of the peripheral injection of MDCT scanning.
22-24
Herein, we will outline the typical process of CBCT scanning that was followed by our institutions. 25 Before CBCT scanning, angiography of the celiac trunk and superior mes- Because the C-arm rotation time (5-10 seconds) was longer in CBCT than MDCT, breath-hold was important to obtain high-quality CBCT hepatic arteriograms suitable for superselective chemoembolization. In our previous study, the image quality of CBCT hepatic arteriography was good enough to trace subsegmental hepatic arteries in about 90% of patients. 25 Diaphragmatic motion was the most significant determinant of image quality, and CBCT could not be per- 
Detection of fine tumor-feeding arteries
Out of the 228 tumor-feeding arteries of 142 tumors (1.99 ±1.03 cm in diameter; range, 0.5-4.9 cm) investigated in our study, 97.4% could be detected and 95.2% could be traced from the common hepatic artery to the tumor on the MPR and MIP images of CBCT. 35 As a result, subsegmental superselective chemoembolization could be performed using CBCT hepatic arteriography without any additional angiography in >90% of the tumors in 85% of the patients. In the recently published systemic review and meta-analysis, CBCT can significantly increase the detection of tumor-feeding arteries during chemoembolization. 36 
3D roadmap and automated vessel tracking system
Some studies have reported the technique of automated 
Recognition of extrahepatic collateral blood supply
At the initial presentation, HCCs with subcapsular location or exophytic growth might be receiving extrahepatic collateral supply. Extrahepatic collateral supply is more common in the bigger tumors. During repeated treatment sessions, the likelihood of extrahepatic supply for residual or recurrent tumor further increases. 40 Therefore, the recognition of parasitic supply through extrahepatic collateral arteries is essential to achieve a successful outcome after chemoembolization. 41, 42 It is not easy to detect the extrahepatic collateral supply to 
Prevention of non-target embolization
CBCT is highly recommended to improve the safety of chemoembolization by preventing or minimizing non-target embolization. Because CBCT hepatic arteriography provides more accurate information of the tumor location and tumorfeeding arteries, the area of liver damage can be minimized. 44 reported that intraprocedural monitoring using CBCT could decrease local tumor recurrence after the chemoembolization of small HCCs.
Improvement of therapeutic efficacy of chemoembolization
With these advantages of CBCT in chemoembolization, it is expected to improve local tumor control and overall survival rates of patients with HCC. Iwazawa et al. 45 conducted a retrospective study comparing chemoembolization with and without CBCT assistance and reported significant improvement in the progression-free survival rates (94%, 81%, and 71% with CBCT, and 79%, 65%, and 41% without, at 1-, 2-, and 3-years, respectively) and overall survival rates (43%, 31%, and 26% with CBCT, and 27%, 10%, and 5% without, at 1-, 2-, and 3-years, respectively). Further prospective studies should be conducted to confirm the advantage of CBCTassisted chemoembolization with survival rates.
RADIATION DOSE OF CBCT GUIDANCE IN CHEMOEMBOLIZATION
The radiation dose of CBCT depends on the scan mode, angiography system, and manufacturer. According to our study using DynaCT (Siemens, Erlangen, Germany), the mean dose area product (DAP) and standard deviation (SD) 
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